TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis
USA - NASDAQ:TGTX - US88322Q1085 - Common Stock
34.55 USD
+0.86 (+2.55%)
34.5 USD
-0.05 (-0.14%)
Overall TGTX gets a fundamental rating of 5 out of 10. We evaluated TGTX against 534 industry peers in the Biotechnology industry. TGTX has an average financial health and profitability rating. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
TGTX had positive earnings in the past year.
In the past year TGTX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
TGTX has a better Return On Assets (8.60%) than 92.88% of its industry peers.
TGTX has a Return On Equity of 21.87%. This is amongst the best in the industry. TGTX outperforms 96.25% of its industry peers.
TGTX's Return On Invested Capital of 12.78% is amongst the best of the industry. TGTX outperforms 95.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.6% | ||
| ROE | 21.87% | ||
| ROIC | 12.78% |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 13.31%, TGTX belongs to the best of the industry, outperforming 92.88% of the companies in the same industry.
TGTX has a Operating Margin of 18.91%. This is amongst the best in the industry. TGTX outperforms 94.01% of its industry peers.
Looking at the Gross Margin, with a value of 86.96%, TGTX belongs to the top of the industry, outperforming 89.33% of the companies in the same industry.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.91% | ||
| PM (TTM) | 13.31% | ||
| GM | 86.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TGTX has more shares outstanding
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
The debt/assets ratio for TGTX is higher compared to a year ago.
2.2 Solvency
TGTX has an Altman-Z score of 6.43. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.43, TGTX is in the better half of the industry, outperforming 75.47% of the companies in the same industry.
TGTX has a Debt/Equity ratio of 0.89. This is a neutral value indicating TGTX is somewhat dependend on debt financing.
TGTX has a Debt to Equity ratio of 0.89. This is in the lower half of the industry: TGTX underperforms 75.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.43 |
ROIC/WACC1.48
WACC8.64%
2.3 Liquidity
A Current Ratio of 3.86 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a Current ratio (3.86) which is in line with its industry peers.
TGTX has a Quick Ratio of 2.96. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a worse Quick ratio (2.96) than 62.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.86 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
TGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.33%.
The Revenue has grown by 30.96% in the past year. This is a very strong growth!
The Revenue has been growing by 364.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%
3.2 Future
TGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 100.43% yearly.
Based on estimates for the next years, TGTX will show a very strong growth in Revenue. The Revenue will grow by 38.77% on average per year.
EPS Next Y451.63%
EPS Next 2Y268.12%
EPS Next 3Y154.33%
EPS Next 5Y100.43%
Revenue Next Year83.46%
Revenue Next 2Y65.34%
Revenue Next 3Y50.3%
Revenue Next 5Y38.77%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 93.38, TGTX can be considered very expensive at the moment.
91.01% of the companies in the same industry are more expensive than TGTX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.83, TGTX is valued quite expensively.
A Price/Forward Earnings ratio of 18.21 indicates a rather expensive valuation of TGTX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 94.01% of the companies listed in the same industry.
TGTX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 93.38 | ||
| Fwd PE | 18.21 |
4.2 Price Multiples
90.64% of the companies in the same industry are more expensive than TGTX, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 60.73 |
4.3 Compensation for Growth
TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TGTX may justify a higher PE ratio.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 154.33% in the coming years.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y268.12%
EPS Next 3Y154.33%
5. Dividend
5.1 Amount
No dividends for TGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
34.55
+0.86 (+2.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners64.52%
Inst Owner Change-0.53%
Ins Owners9.73%
Ins Owner Change0.3%
Market Cap5.48B
Revenue(TTM)454.07M
Net Income(TTM)60.46M
Analysts78.67
Price Target43.18 (24.98%)
Short Float %16.62%
Short Ratio12.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.54%
Min EPS beat(2)-83.83%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-15.86%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)4
Avg EPS beat(8)69.34%
EPS beat(12)6
Avg EPS beat(12)43.68%
EPS beat(16)8
Avg EPS beat(16)35.05%
Revenue beat(2)1
Avg Revenue beat(2)-3.03%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)0.05%
Revenue beat(4)3
Avg Revenue beat(4)0.18%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)35.09%
Revenue beat(12)8
Avg Revenue beat(12)17.26%
Revenue beat(16)10
Avg Revenue beat(16)22.77%
PT rev (1m)0.79%
PT rev (3m)1.48%
EPS NQ rev (1m)-3.02%
EPS NQ rev (3m)-9.88%
EPS NY rev (1m)-2.51%
EPS NY rev (3m)-2.72%
Revenue NQ rev (1m)-0.51%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-1.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 93.38 | ||
| Fwd PE | 18.21 | ||
| P/S | 12.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 19.83 | ||
| P/tB | 19.83 | ||
| EV/EBITDA | 60.73 |
EPS(TTM)0.37
EY1.07%
EPS(NY)1.9
Fwd EY5.49%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS2.86
BVpS1.74
TBVpS1.74
PEG (NY)0.21
PEG (5Y)N/A
Graham Number3.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.6% | ||
| ROE | 21.87% | ||
| ROCE | 16.18% | ||
| ROIC | 12.78% | ||
| ROICexc | 24.32% | ||
| ROICexgc | 24.32% | ||
| OM | 18.91% | ||
| PM (TTM) | 13.31% | ||
| GM | 86.96% | ||
| FCFM | N/A |
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score3
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.85 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 3.33 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.86 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | 6.43 |
F-Score3
WACC8.64%
ROIC/WACC1.48
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y451.63%
EPS Next 2Y268.12%
EPS Next 3Y154.33%
EPS Next 5Y100.43%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%
Revenue Next Year83.46%
Revenue Next 2Y65.34%
Revenue Next 3Y50.3%
Revenue Next 5Y38.77%
EBIT growth 1Y-15.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year433.86%
EBIT Next 3Y127.45%
EBIT Next 5YN/A
FCF growth 1Y63.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.11%
OCF growth 3YN/A
OCF growth 5YN/A
TG THERAPEUTICS INC / TGTX FAQ
What is the fundamental rating for TGTX stock?
ChartMill assigns a fundamental rating of 5 / 10 to TGTX.
Can you provide the valuation status for TG THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.
Can you provide the profitability details for TG THERAPEUTICS INC?
TG THERAPEUTICS INC (TGTX) has a profitability rating of 6 / 10.
What are the PE and PB ratios of TG THERAPEUTICS INC (TGTX) stock?
The Price/Earnings (PE) ratio for TG THERAPEUTICS INC (TGTX) is 93.38 and the Price/Book (PB) ratio is 19.83.
How financially healthy is TG THERAPEUTICS INC?
The financial health rating of TG THERAPEUTICS INC (TGTX) is 4 / 10.